Who invested in Hemab

One round we have observed, with the 4 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$157Mraised across 1 round since 2025, from 1 source

Latest round: Series C, $157MOct 2025
Investors: 4

See who backed them

The rounds

Oct 2025
Series C$157M
Source recorded

Founders and team

From Hemab's own website: 15 on the team.

Angela VolkertVice President, Clinical Research
Erik BjornsonVice President, Regulatory Affairs
Karen WeisbachChief People and Culture Officer
Eva BøgeSenior Director, Regulatory Affairs
Jennifer DupeeExecutive Assistant/Office Manager
Keli WalbertDirector
Leyna ChoSenior Clinical Trial Associate
Louise Almsgaard HeltSenior Finance Business Partner
Maj Invest EquitySenior Finance Business Partner
Matthew BandelSenior Clinical Trial Associate
Michelle FisherDirector, Data Management
Per JeppesenDirector, CMC Drug Product Development
Shea GoldenSenior Clinical Trial Associate
Shivangi MathyAssociate Director, Clinical Operations
Tara ParsonsAssociate Director, Clinical Operations

Everyone who backed them

RA Capital ManagementPrivate equity1round

Sofinnova PartnersVC firm1round

Novo HoldingsVC firm1round

InvusPrivate equity1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Hemab as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.